FY2017 Earnings Forecast for Aduro Biotech, Inc. Issued By Oppenheimer Holdings (ADRO)
Aduro Biotech, Inc. (NASDAQ:ADRO) – Equities research analysts at Oppenheimer Holdings issued their FY2017 earnings per share (EPS) estimates for Aduro Biotech in a note issued to investors on Monday. Oppenheimer Holdings analyst M. Breidenbach forecasts that the biotechnology company will post earnings per share of ($1.38) for the year. Oppenheimer Holdings has a “Buy” rating and a $15.00 price target on the stock. Oppenheimer Holdings also issued estimates for Aduro Biotech’s Q1 2018 earnings at ($0.41) EPS, Q2 2018 earnings at ($0.42) EPS, Q3 2018 earnings at ($0.43) EPS, Q4 2018 earnings at ($0.42) EPS, FY2018 earnings at ($1.67) EPS, FY2019 earnings at ($1.90) EPS and FY2021 earnings at ($0.78) EPS.
Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.03). The firm had revenue of $3.79 million for the quarter, compared to the consensus estimate of $4.04 million. Aduro Biotech had a negative return on equity of 40.04% and a negative net margin of 548.92%. The firm’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.54) earnings per share. TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/02/fy2017-earnings-forecast-for-aduro-biotech-inc-issued-by-oppenheimer-holdings-adro.html.
A number of other research firms also recently weighed in on ADRO. BidaskClub raised Aduro Biotech from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Cowen and Company assumed coverage on Aduro Biotech in a research note on Tuesday, July 18th. They set an “outperform” rating on the stock. Zacks Investment Research downgraded Aduro Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. HC Wainwright set a $18.00 price target on Aduro Biotech and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, Canaccord Genuity set a $30.00 price target on Aduro Biotech and gave the stock a “buy” rating in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $19.14.
In other Aduro Biotech news, VP Blaine Templeman sold 2,884 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $11.20, for a total transaction of $32,300.80. Following the completion of the sale, the vice president now directly owns 58,834 shares of the company’s stock, valued at approximately $658,940.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Stephen T. Isaacs sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $12.19, for a total value of $487,600.00. Following the sale, the chief executive officer now directly owns 144,025 shares of the company’s stock, valued at $1,755,664.75. The disclosure for this sale can be found here. Insiders have sold a total of 342,745 shares of company stock valued at $3,956,397 over the last three months. Corporate insiders own 6.60% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Baillie Gifford & Co. increased its holdings in Aduro Biotech by 30.8% during the 3rd quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock worth $5,891,000 after purchasing an additional 130,390 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in Aduro Biotech during the 3rd quarter worth approximately $127,000. The Manufacturers Life Insurance Company increased its holdings in Aduro Biotech by 12.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 33,964 shares of the biotechnology company’s stock worth $388,000 after purchasing an additional 3,769 shares in the last quarter. State Street Corp increased its holdings in Aduro Biotech by 8.3% during the 2nd quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock worth $7,808,000 after purchasing an additional 52,597 shares in the last quarter. Finally, Nexthera Capital LP bought a new stake in Aduro Biotech during the 2nd quarter worth approximately $1,767,000. 35.24% of the stock is owned by hedge funds and other institutional investors.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.